MoonLake Immunotherapeutics (MLTX) Eyes FDA Nod for Sonelokimab Amid Mixed Market Signals
· gurufocus.com
On October 18, 2026, MoonLake Immunotherapeutics (NASDAQ: MLTX) expressed optimism about the FDA's potential acceptance of its biologics license application (BL
On October 18, 2026, MoonLake Immunotherapeutics (NASDAQ: MLTX) expressed optimism about the FDA’s potential acceptance of its biologics license application (...